BioSpace News Archive

Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development.

RedHill Biopharma Ltd. (NASDAQ: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today reported its first quarter 2023 financial results and operational highlights.

Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (AST) solutions announced today the submission of its eQUANTTM system for FDA 510(k) clearance.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of a new analysis from the N-MOmentum clinical trial of UPLIZNA demonstrating the utility of a robust adjudication process that could improve clinical care decision-making in neuromyelitis optica spectrum disorder (NMOSD) through more accurate and consistent assessment of disease-related attacks.

SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced the appointment of Rohan Seth as Chief Financial Officer.

Masimo and Community Health System, based in Fresno, California, announced that CHS is adopting a variety of advanced Masimo monitoring technologies and solutions across its campuses.

Ambulero, Inc. is developing a first-in-class gene and cell therapy platform for treating serious vascular diseases and non-healing wounds where amputation is a care option.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”) announced today its submission of a 510(k) application to the U.S. Food and Drug Administration (FDA) for its OneRF™ Ablation System.

Geron Corporation, a late-stage clinical biopharmaceutical company, announced new data and analyses from IMerge Phase 3 reporting robust durability of transfusion independence, evidence for disease-modifying activity and favorable fatigue patient-reported outcomes in lower risk myelodysplastic syndromes patients treated with the Company’s first-in-class telomerase inhibitor, imetelstat, vs. placebo.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announces its participation in the upcoming GCFF Innovation & Healthcare virtual conference on June 15, 2023.